Does the Accession of PDE5 Inhibitors to Antihypertensive Agents Modification Their Adverse Events?

In studies in which viagra versus medication was administered to patients on antihypertensive medical specialty, there was no alteration in discussion discontinuations owing to adverse events in patients receiving viagra . In a cogitation by Kloner et al., the optical phenomenon of treatment-related adverse events potentially related to the reduction of BP (hypotension, flushing, dizziness) was not different in patients receiving sildenafil plus no antihypertensive medicines, versus sildenafil plus 1, 2 or ≥3 antihypertensive medicines.
Furthermore, there were no patients who developed heart disease, coronary thoroughfare disease or myocardial infarction when viagra was administered on top of antihypertensive medicine.
In a reflection by Pickering et al., idiom adverse events related to sildenafil , such as aching, flushing, dyspepsia and others, were similar among patients who were taking multiple antihypertensive medications to those that had been reported for patients on viagra not on antihypertensives.
Also, there was no increased relative frequency of adverse events (except flushing) in patients receiving cialis and digit or multiple antihypertensive agents. In studies assessing the use of vardenafil in patients on antihypertensive medicines, there was no gain in adverse events. Thus, PDE5 inhibitors can be safely administered with usual antihypertensive agents including diuretics, beta blockers, calcium blockers and angiotensin structure blockers.
This is a part of article Does the Accession of PDE5 Inhibitors to Antihypertensive Agents Modification Their Adverse Events? Taken from "Cialis Compare Levitra Viagra" Information Blog